Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

Moleculin's Annamycin Shows Strong Efficacy Trends in R/R AML Interim Analysis

Moleculin Biotech announced positive preliminary unblinded efficacy results from the first 45 patients in Part A of its pivotal Phase 2/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (R/R AML). Both Annamycin treatment arms, combined with HiDAC, demonstrated favorable efficacy trends compared to the HiDAC control arm. Complete remission (CR) rates were 43% and 36% for the Annamycin cohorts (190 mg/m² and 230 mg/m² respectively), significantly outperforming the 12% observed in the control arm. Composite complete remission (CRc) rates were also higher at 50% and 57% versus 29% for control. These promising results, measured after a single cycle of therapy, led the Independent Data Monitoring Committee (iDMC) to recommend continuing the trial.

• The interim analysis of the MIRACLE trial revealed compelling efficacy for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML). The 190 mg/m² Annamycin arm achieved a 43% complete remission (CR) rate, while the 230 mg/m² arm showed a 36% CR rate, both substantially higher than the 12% seen in the HiDAC control arm. Furthermore, composite complete remission (CRc) rates were 50% and 57% for the Annamycin arms, compared to 29% for control, demonstrating a clear advantage after just one treatment cycle.
• Despite the absence of formal statistical significance at this early interim analysis, the Independent Data Monitoring Committee (iDMC) unanimously concluded there was a strong numeric trend favoring the experimental Annamycin treatment arms. The iDMC recommended continuing the trial as planned, noting that the trial's prespecified statistical design, which uses a conservative O’Brien-Fleming spending function, reserves most statistical power for the final analysis, making significance at this stage neither expected nor required.
• The MIRACLE trial is a pivotal Phase 2/3, multi-center, randomized, double-blind, placebo-controlled, adaptive design study evaluating Annamycin as second-line therapy for R/R AML. Part A aims to identify the optimal Annamycin dose, with 67 of the targeted 90 patients already enrolled. The interim n=45 population included challenging patients, with 75.6% over 60 years of age, 55.6% having received 7+3, and 31.1% pretreated with venetoclax regimens for first-line therapies.

The Persistent Unmet Needs in Relapsed/Refractory AML

Despite meaningful therapeutic advances, relapsed/refractory (R/R) AML remains a disease with profoundly poor outcomes — more than 60% of patients who achieve re-emission ultimately relapse, and no complete cure has been established. The landscape is defined by intersecting challenges: persistent drug resistance, immune evasion by leukemic cells, and the absence of regulatory-approved cellular therapies, underscoring the breadth of unmet need across both biological and clinical dimensions.

• Patients with R/R AML broadly continue to represent a critical unmet population, as relapse and drug resistance remain major threats despite the effectiveness of chemotherapy and targeted therapy; outcomes of both traditional and novel therapies remain unsatisfactory, and most patients who relapse face dismal salvage options.

• FLT3-mutated R/R AML is an active area of development, with second-generation inhibitors gilteritinib and quizartinib being evaluated — including in doublet and triplet regimens with venetoclax — though questions persist on optimal application in complex relapsed/refractory settings.

• TP53-mutated AML (approximately 5–10% of AML cases, classified as unfavorable risk) represents one of the most challenging subgroups; hypomethylating agent/venetoclax-based regimens yield improved initial responses, but remissions are generally short-lived and overall survival remains poor, with no optimal treatment regimen yet established.

• IDH1/2-mutated AML has seen a paradigm shift toward targeted therapy, with IDH1 inhibitors (ivosidenib, olutasidenib) and the IDH2 inhibitor enasidenib providing meaningful responses; triplet regimens combining azacitidine or oral decitabine with venetoclax and an IDH inhibitor have demonstrated composite complete remission rates of 92% and 2-year overall survival of 69%.

• NPM1-mutated and KMT2A-rearranged AML are emerging target populations for menin inhibitors (revumenib and ziftomenib), which are producing meaningful remission rates in the R/R setting.

• Older adults and patients with high-risk molecular features who are ineligible for intensive chemotherapy or allogeneic stem cell transplantation remain historically underserved; oral targeted agents are being prioritized for these patients given superior tolerability profiles.

• Immunotherapy-ineligible and immune-evasive disease represents a broad unmet need — AML's immunosuppressive tumor microenvironment, driven by hypoxia, high lactic acid levels, nutrient competition, and T cell exhaustion, significantly hampers antitumor immune responses; checkpoint inhibitors, CAR-T cells targeting CD33, CD123, and CLL-1, TCR-T therapies targeting WT1, and STING agonists are in development, though no cellular product has yet achieved regulatory approval and the preclinical-to-clinical translation gap remains a significant challenge.

• Leukemia stem cells (LSCs) are an increasingly prioritized target, as they are central to treatment resistance and disease relapse; immunotherapeutic strategies capable of eliminating LSCs are under active investigation as a means of achieving durable remission.

Annamycin's Promising Interim Efficacy in the MIRACLE Trial

Recent clinical investigations in relapsed/refractory AML (R/R AML) have evaluated a range of combination regimens and targeted agents, with outcomes varying considerably by prior treatment exposure and disease biology. The studies summarized below reflect findings from phase 1 trials, retrospective analyses, and indirect treatment comparisons published in 2025–2026.

Annamycin's Early Promise: A New Path for R/R AML

The recent announcement of positive preliminary efficacy results for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML) marks a potentially pivotal moment for patients facing this aggressive and often treatment-resistant cancer. With complete remission rates significantly higher than the control arm after just one cycle, Annamycin is showing a strong early signal of clinical activity.

What makes Annamycin particularly compelling is its unique pharmacological profile. Unlike conventional anthracyclines such as doxorubicin, Annamycin has been engineered to overcome key challenges in cancer therapy:

• Circumventing Multidrug Resistance (MDR): Research indicates Annamycin can bypass resistance mechanisms mediated by P-glycoprotein (P-gp) and the multidrug resistance-associated protein (MRP), which are frequently implicated in treatment failure in AML.

• Reduced Cardiotoxicity: Studies suggest Annamycin exhibits significantly lower cardiotoxic activity compared to doxorubicin, a critical advantage given the cumulative cardiac burden associated with anthracycline use.

These properties suggest Annamycin could offer a much-needed therapeutic alternative for patients who have exhausted standard options. The strong early data could accelerate its path to market, potentially providing a new standard of care in R/R AML. Furthermore, the validation of its MDR-circumventing mechanism could pave the way for its investigation in other cancers where anthracycline resistance is a significant barrier.

However, it is crucial to approach these early unblinded results with appropriate caution. As with any preliminary data, the full safety and efficacy profile will only become clear with larger, blinded studies. The complex and cell-type-dependent nature of anthracycline action means that while initial results are promising, the drug's behavior in a broader patient population may reveal nuances. Additionally, as a hydrophobic drug, Annamycin's pharmacokinetics can be influenced by patient-specific factors like lipid metabolism, which could impact dosing and efficacy. Continued rigorous evaluation will be essential to fully understand Annamycin's potential and its optimal role in the evolving AML treatment landscape.